GO Capital is an independent management company and a major player in regional Seed and Venture Capital since 2003. With offices in Brittany, Pays de la Loire, Normandy, Centre-Val de Loire and the South of France, GO Capital contributes to the financing of responsible innovation in these regions. With a team of investors with complementary sectoral experience, we have a solid track-record in DeepTech. GO Capital has nearly 400 million euros under management, and mainly finances technology leaders in the digital and healthcare sectors and in the industry of the future.

GO CAPITAL

Demeter is a major player in venture capital and private equity for the energy and ecological transition. They invest from 500 K€ to 30 M€ to support companies at all stages of their development: innovative startups, high growth SMEs and infrastructure projects.

Demeter

Credit Agricole is a universal banking corporation active with focuses on corporate and investment banking, retail banking, insurance, consumer finance and savings management. Crédit Agricole Group is serving 54 million customers (Individuals, farmers, small businesses, local authorities, institutions, corporates) across 46 countries Crédit Agricole is : - Number 1 provider of financing to the French economy (Internal source: ECO 2023) - Number 1 European asset manager with its subsidiary Amundi (Source: IPE “Top 500 Asset Managers”, June 2023) - Number 1 insurer in France (Source: L’Argus de l’assurance, 13 December 2023 - data at end-2022) - Number 1 retail bank in the European Union based on number of customers - 9th largest global bank by balance sheet size (Source: The Banker 2024) Crédit Agricole Group supports its customers in their plans and projects in France and around the world, through its operations in all segments of the market including insurance, real estate, payment systems, asset management, leasing and factoring, consumer finance, and corporate and investment banking.  Crédit Agricole also stands out for its dynamic, innovative corporate social responsibility policy serving the economy. This policy is based on a pragmatic approach that permeates throughout the entire Group and engages all its employees. Its recent inclusion in the Vigeo-NYSE Euronext extra-financial indices is recognition of this engagement.

Crédit Agricole

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.

Bpifrance

Angels Santé is the leading French Business Angel Network solely dedicated to Healthcare investments.

Angels Santé

WinEquity is an investment company founded by investors - entrepreneurs who actively finance and support innovative startups that have at least one woman in the founding team.

WinEquity

Healshape

Healshape creates natural breast reconstruction solutions for all women. Healshape is a biotech startup focused on regenerative medicine.

Healshape is a regenerative medicine company based in Lyon, France that has developed a 3D printed, bioabsorbable breast implant for breast reconstruction after mastectomy. The company's bioprosthesis is made from a patented, natural hydrogel biomaterial that is 3D printed into a customized shape based on the patient's anatomy. After implantation, the bioprosthesis acts as a temporary scaffold that is absorbed by the body over six to nine months, while the patient's own fat cells colonize and regenerate new breast tissue.

Goodbye silicone? A new era of breast reconstruction is on the horizon

3D Printing Applications in the Fight Against Breast Cancer

3D Printed Breast Reconstruction to Get $6.8M Boost - 3DPrint.com

Soft tissue natural reconstruction

3 FemTech startups to keep an eye on in 2023

Novel 3D-printed technologies may replace silicones in breast reconstruction

Seed Of The Week: Healshape

Healshape to raise $6.8M to advance its breast implant 3D bioprinting technology

HEALSHAPE - Atlanpole Biotherapies

Lyonbiopôle

Enabling supply of biologically safe tissues and organs using next-gen printing tech

Bioprinting

Healshape developing 3D-printed breast bioprosthesis using patients’ own cells

Healshape is a regenerative medicine company based in Lyon, France that has developed a 3D printed, bioabsorbable breast implant for breast reconstruction after mastectomy. The company's bioprosthesis is made from a patented, natural hydrogel biomaterial that is 3D printed into a customized shape based on the patient's anatomy. After implantation, the bioprosthesis acts as a temporary scaffold that is absorbed by the body over six to nine months, while the patient's own fat cells colonize and regenerate new breast tissue.
Healshape's technology aims to provide a minimally invasive breast reconstruction option that avoids the use of synthetic implants or complex surgical procedures involving tissue flaps from other parts of the body. The bioprosthesis is designed to be combined with a fat transfer procedure, where the patient's own adipose tissue is used to promote natural tissue regeneration within the implanted scaffold. This approach enables women to regain their breasts through the growth of their own tissue, without any residual foreign material remaining in the body.
Healshape was founded in January 2020 and has developed its bioprinting technology based on patents and expertise from the University of Lyon's Institute for Molecular and Supramolecular Chemistry and Biochemistry (ICBMS) and LabSkin Creations. The company raised EUR 6 million in seed funding in 2022 to advance its bioprosthesis toward clinical trials.

3D Bioprinting Solutions is a Russian biotechnology research laboratory focused on developing and commercializing bioprinting technologies. The company was founded by INVITRO, the largest private medical company in Russia, and officially opened its 3D Bioprinting Solutions laboratory in September 2013. Its core activities involve the development and production of bioprinters, bioinks, and biofabrication technologies for regenerative medicine and drug discovery applications.
One of the company's key products is the FABION bioprinter, capable of bioprinting without the need for organic or artificial scaffolds using a proprietary nanotechnology approach. In 2016, 3D Bioprinting Solutions launched the FABION 2, an advanced bioprinter that can print complex structures using tissue spheroids and a wide range of hydrogels with different polymerization mechanisms. The FABION two features a unique laser positioning system with an accuracy of five micrometers, enabling the printing of highly intricate structures.
In 2018, the company delivered its Organ.Aut magnetic 3D bioprinter to the International Space Station (ISS) for conducting experiments in microgravity conditions. The Organ.Aut successfully bioprinted a mouse's thyroid gland in space in December 2018, marking the first instance of living tissue being printed in outer space. In August 2019, the company bioprinted bone tissue aboard the ISS using the Organ.Aut.
3D Bioprinting Solutions has actively pursued collaborations with research institutions and commercial entities worldwide. In April 2019, the company announced plans to collaborate with laboratories from the US and Israel to deliver muscular tissue biomaterials to the ISS for bioprinting experiments using the Organ.Aut bioprinter.

3D Bioprinting Solutions

A.D.A.M. Bioprinting is a company developing an on-demand 3D bioprinting platform for manufacturing personalized implants. Their core technology, a Medical Device Production System, enables medical professionals to complete the entire process of 3D modeling, printing, and sterilization to create customized implants ready for implantation.
The company's initial focus is on producing orthopaedic bone implants for cranial, maxillofacial, general trauma, and orthopaedic oncology surgeries. However, A.D.A.M. Bioprinting plans to expand its offerings to include printed soft tissues in the future.
Founded in 2018, A.D.A.M. Bioprinting has its roots in Ukrainian aerospace and biotech engineering. The company operates with a research and development office in Ukraine, while its US-based entity holds intellectual property and handles business development and marketing functions.
In May 2022, A.D.A.M. Bioprinting was accepted into Elementa Labs, the virtual incubator program of the Mount Sinai Health System in New York. This program aims to optimize, expand, and advance the company's core technology platform, potentially leading to its commercialization in the US market.

A.D.A.M.

Advanced BioMatrix, a San Diego-based biotechnology company, develops advanced biomaterials and reagents for 3D cell culture applications, including cell cultivation, cell assays, bioprinting, and cell proliferation. The company's products have been utilized in groundbreaking research for drug development and 3D bioprinted tissue models, with over 5,000 citations in scientific publications as of September 2021. Advanced BioMatrix's offerings include hydrogels that mimic the extracellular matrix, facilitating cellular attachment, survival, and compatibility with various tissue types.
In September 2021, Advanced BioMatrix was acquired by BICO Group AB, a Swedish bioconvergence company focused on enhancing biology research, for approximately USD 15 million. Following the acquisition, Advanced BioMatrix became a subsidiary of CELLINK Bioprinting, operating under the BICO Group. The company generated approximately USD 3 million in revenue with an adjusted EBITDA margin of around 50% in its latest fiscal year prior to the acquisition.
Key customers and partnerships
Advanced BioMatrix has established collaborations with research institutes, pharmaceutical companies, and life science organizations worldwide. In June 2022, the company expanded its existing partnership with Lineage Cell Therapeutics for Lineage's HyStem cell/drug delivery technology, broadening its focus on manufacturing and supplying research-grade HyStem to the research community and developing clinical/commercial-grade material for Lineage's customers.
In August 2023, Advanced BioMatrix signed a distribution agreement with InSphero AG, a pioneer in 3D cell culture and organ-on-chip technology, to make InSphero's patented Akura Plate Technology available to researchers in the US market. This collaboration aims to expand the application range for scientists and drug developers by combining Advanced BioMatrix's biomaterials with InSphero's Akura Plates for scaffold-based organoid and spheroid cultures.

Advanced Biomatrix

Advanced Solutions Life Sciences, a wholly-owned subsidiary of Advanced Solutions, Inc., is a global leader in 3D biofabrication, headquartered in Louisville, Kentucky. The company pioneered the BioAssemblyBot, the world's first 6-axis robotic human tissue printer capable of systematically reproducing organoids. Their patented 3D printed blood vessel technology, derived from human fat tissue, empowers customers to advance the science of 3D organ printing. Advanced Solutions Life Sciences offers expertise in regenerative medicine, bioinks, 3D tissue assays for drug discovery and testing, 3D tissue modeling, and 3D printing services.
In May 2018, the company expanded its operations by opening a second biofabrication facility and laboratory in Manchester, New Hampshire. This strategic expansion aimed to contribute to curative organ printing solutions and establish the company as a prominent corporate citizen in Manchester.
In January 2023, Advanced Solutions Life Sciences partnered with Molecular Devices, a bioscience company, to develop 3D biology automation solutions. They jointly developed the BioAssemblyBot 400 (BAB 400) for Drug Discovery, integrating Advanced Solutions' bioprinting platform with Molecular Devices' ImageXpress Cellular Imaging System. This automated platform enables consistent, large-scale production of organoid models, enhancing drug discovery research.

Advanced Solutions Life Sciences

Allegro 3D is a bioprinting company specializing in high-throughput and high-precision 3D printing technology for fabricating tissue models at an industrial scale. The company was acquired by BICO, a Swedish bioconvergence company, in May 2022 for an upfront enterprise value of USD 6 million. Allegro 3D's patented light-based digital light processing (DLP) bioprinting technology enables direct printing into multi-well plates, allowing customers to significantly increase their output of biofabricated constructs for applications in regenerative medicine and drug discovery workflows. The company's flagship product, the STEMAKER Model D, utilizes extrusion-based bioprinting to produce bio/organic parts using liquid feedstock. As of 2022, Allegro 3D was expected to generate approximately USD 1 million in revenue with positive EBITDA margins. The acquisition complements BICO's existing portfolio of bioprinters and strengthens its position as a global leader in providing bioprinting solutions.

Allegro 3D

Developing and selling bioprinter devices that can be used by hospitals, research institutes, and other organizations seeking to print biological substitutes and materials.

Companies that use propietary or third-party printers to produce and sell bioprinted tissues, including impants, organ replacement, and other types of tissues.

Companies that are developing materials and bioinks, that can be used in bioprinting devices. This includes material technologies and nanofibers.

Developing software solutions and applications for designing and managing the bioprinting production process.

3D printing enables bioprinting devices, which rely on a similar design and operating model

Startups in this hub are able to customize the bioprinted models to suit each patient

AI/ML is used in the design and optimization of 3D models that can be bioprinted

Healshape

Sources

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless